GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2022-01-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 396
- Registration Number
- NCT04386616
- Locations
- 🇺🇸
Torrance Memorial Medical Center, Torrance, California, United States
🇺🇸Lehigh Valley Health Network, Allentown, Pennsylvania, United States
🇺🇸Albany Medical Center, Albany, New York, United States
Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab.
- First Posted Date
- 2020-05-06
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 179
- Registration Number
- NCT04377555
- Locations
- 🇺🇸
Shepherd Center Inc., Atlanta, Georgia, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸SUNY Upstate Medical University, Syracuse, New York, United States
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 377
- Registration Number
- NCT04372186
- Locations
- 🇺🇸
eStudySite, La Mesa, California, United States
🇺🇸El Centro Regional Medical Center, El Centro, California, United States
🇺🇸Highland Hospital Oakland, Oakland, California, United States
A Study Of ¹²⁹XE MRI To Assess Disease Progression In Patients With COPD Treated With Or Without Azithromycin And Standard-of-Care Medications
- Conditions
- Interventions
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04353661
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸Duke Asthma Allergy and Airway Center, Durham, North Carolina, United States
🇺🇸University of Virginia Health System, Charlottesville, Virginia, United States
A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT04302025
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸UCLA Hematology Oncology, Los Angeles, California, United States
🇺🇸Karmanos Cancer Institute - Farmington Hills/Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States
Evaluation of the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Females of Non-Childbearing Potential
- Conditions
- First Posted Date
- 2020-02-18
- Last Posted Date
- 2021-04-28
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04274075
- Locations
- 🇺🇸
Covance Research Unit - Daytona, Daytona Beach, Florida, United States
An Expanded Access Program for Risdiplam in Participants With Spinal Muscular Atrophy (SMA)
- Conditions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT04256265
- Locations
- 🇺🇸
Arkansas Children's Hospital; Pediatrics, Little Rock, Arkansas, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Ann and Robert H. Lurie Children Hospital of Chicago, Chicago, Illinois, United States
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT04250155
- Locations
- 🇳🇱
VU Medisch Centrum, Amsterdam, Netherlands
🇳🇱Universitair Medisch Centrum Groningen, Groningen, Netherlands
🇪🇸Clinica Universitaria de Navarra, Pamplona, Navarra, Spain
A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT04195958
- Locations
- 🇺🇸
Swedish Health Services, Seattle, Washington, United States
🇺🇸Broward Research Center, Pembroke Pines, Florida, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Prospective Clinicogenomic Program
- Conditions
- Interventions
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 945
- Registration Number
- NCT04180176
- Locations
- 🇺🇸
Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸Ironwood Cancer & Research Centers, Chandler, Arizona, United States
🇺🇸University Cancer & Blood Center, LLC; Research, Athens, Georgia, United States